Back to Regeneron

Regeneron News

REGN

Regeneron and Sanofi Amend Antibody Deal — REGN

Regeneron (REGN) and Sanofi settle a lawsuit and expand antibody co‑development. Key implications for collaboration revenue, EYLEA franchise and patent risk. (2026-10-06)

6 October 2026REGENERON PHARMACEUTICALS, INC.
REGN

Regeneron Grants Long-Term PSUs to CEO, CSO

Regeneron (REGN) awards long-term PSUs to CEO and CSO tied to 10-year growth goals; context on EYLEA revenue concentration, patents, collaborations, and risks.

30 September 2026REGENERON PHARMACEUTICALS, INC.
REGN

Regeneron Forms Subsidiary to Explore Non-Core Assets

Regeneron (REGN) creates a majority-owned subsidiary to explore non-core business; implications for EYLEA concentration, collaborations, and risk profile.

30 September 2026REGENERON PHARMACEUTICALS, INC.
REGN

Regeneron to Record $127M IPR&D Charge in Q2 2026

Regeneron (REGN) will record a $127M pre-tax IPR&D charge in Q2 2026, reducing reported earnings. EYLEA accounted for $7,891M (55%) of 2025 net product sales.

6 July 2026REGENERON PHARMACEUTICALS, INC.
All news